Human pluripotent stem-cells (HPSCs)—including human embryonic stem-cells and human induced pluripotent stem-cells—are reshaping the landscape of regenerative medicine.1,2 In Parkinson's disease, ...

The collaborations will provide Illumina's customers with workflows for genomic disease characterization and spatial mapping.

The field of cancer genetics and oncogenomics is undergoing a transformative shift as multi-omics approaches become central to understanding the complex ...

With an incredibly simple workflow, TruPath Genome eliminates traditional library prep. In just 10-15 minutes of hands-on ...

Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate ...

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a suite o ...

Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.

I try not to think of what would have happened if they had found this at the beginning,” says Runkel. “I find that if I just ...

Studying gene expression in a cancer patient's cells can help clinical biologists understand the cancer's origin and predict the success of different treatments. But cells are complex and contain many ...

Researchers at UChicago have developed a nanoparticle system that can effectively deliver mRNA to insulin-producing cells, protecting them from the body’s autoimmune response ...

Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, ...

High-throughput sequencing, single-cell technologies, and large-scale population studies have transformed genetics and genomics into data-intensive ...